BPC-157 common uses, half-life, side effects and more

BPC-157 is a synthetic peptide of 15 amino acids. Its sequence was first reported as a fragment of a protein found in human gastric juice. The material sold today is made synthetically. People use it mainly in the hope of speeding recovery from tendon, ligament, muscle, and joint injuries. A second common use is for gut problems such as reflux, ulcers, and inflammatory bowel conditions. It is not an approved medicine in any country and is sold as a research chemical. It is also banned in sport at all times.

• Recovery from tendon, ligament, muscle, and joint injuries
• Gut problems such as reflux, ulcers, and inflammatory bowel conditions
• General wound and skin healing
• Recovery after surgery or acute injury
• Frequently combined with TB-500 in a soft-tissue healing stack

One to two times daily

Community protocols most commonly use 250 to 500 mcg subcutaneously once or twice daily. Some users go up to about 1000 mcg per day. People often take 250 to 500 mcg by mouth once or twice daily for gut problems instead. No human trial has ever established a dose by injection. These amounts are community conventions scaled from animal studies. The one registered oral trial used much higher amounts in the range of 1 to 9 mg. It listed absorption measures among its goals and never reported any results.

• People commonly inject it subcutaneously near a local injury for a targeted effect or into the abdomen for a whole-body or gut effect
• Oral dosing is the community choice for gut issues while injection is preferred for muscle and joint injuries
• The two peptides in the common TB-500 stack are reconstituted and injected separately rather than mixed
• Community protocols usually run it for several weeks and then take a break rather than dosing without pause

Animal studies put the plasma half-life under 30 minutes. No dedicated human pharmacokinetic study exists. The short time in the blood contrasts with healing effects reported to last far longer.

• Injection-site redness, swelling, or irritation described by users rather than documented in a trial
• Headache reported in a two-person study of dosing into a vein
• Nausea, dizziness, and fatigue reported by users but not documented in any trial
• Rare reports of shortness of breath or skin darkening that each also involved other peptides

How BPC-157 works is only partly understood. No receptor for it has been identified. Its most reported effect in animal studies is on the growth of new blood vessels. It raises the receptor that vascular growth factor acts through without raising that growth factor itself. It also raises nitric oxide signaling. Cell culture shows no direct vessel-growing effect. Corneal studies show it suppressing new vessels rather than promoting them. The direction of the effect depends on the tissue. Animal work does show better blood flow returning to injured tissue. It also increases the activity of collagen-producing cells and raises growth-hormone receptor levels on tendon cells. This may explain the tendon and ligament effects people report. It also affects dopamine, serotonin, and GABA signaling in animals and protects the stomach lining.

The evidence is weak for human use. Almost all of it comes from animal and laboratory studies. Most of the published research traces to a single research group with little independent replication. No completed and fully published human clinical trial exists for any use. A company drug program studied it by enema for ulcerative colitis in the 2000s. That work never appeared beyond conference abstracts. A registered oral safety trial from 2015 posted no results. The only recent human reports are two small uncontrolled pilots published by one author in a low-tier journal. Preclinical findings are broadly positive and consistent. Consistency within one group is not independent proof.

• Not approved as a medicine in any country and sold only as a research chemical so its purity, identity, dose accuracy, and sterility are unverified
• Banned in sport at all times under WADA section S0 with no realistic therapeutic use exemption
• People with active or recent cancer should avoid it because its effect on tumor growth is untested in humans and no carcinogenicity study exists
• Animal safety studies ran no longer than 28 days and showed altered clotting times and liver-related marker changes that leave anyone on blood thinners unexamined
• Do not use it in pregnancy or while breastfeeding because there is no human safety data
• Human safety data is minimal and the few reported adverse events all involved other substances taken at the same time